More precisely lenalidomide reduces CXCL12 secretion by MDS-derived BM-MSCs and this has been hypothesized to induce the egress of dormant MDS cells from their niches and render them more sensitive to the drug. Here, CXCL12 is linked to myelodysplastic syndrome.